The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
MPN Congress 2021 | Driver mutations in MPNs
Mary Frances McMullin, MD, Queens University Belfast, Belfast, UK, outlines the main driver mutations in myeloproliferative neoplasms (MPNs). Almost 95% of patients with polycythemia vera harbour a single point mutation in JAK2, JAK2 V167F, and a small portion carries JAK2 exon 12 mutations or other JAK2 mutations. In contrast, only 50% of patients with essential thrombocythemia carry the JAK2 V167 mutations and the other half harbour mutations in MPL and CALR, similarly to patients with myelofibrosis. Triple-negative patients carry other currently unknown driver mutations. This interview took place at the 2021 International Congress on MPNs congress in New York, NY.
